Literature DB >> 17425910

The role of PPAR-alpha agonists in the prevention of CVD in diabetes.

Marja-Riitta Taskinen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17425910     DOI： 10.1007/s11892-007-0014-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   5.430


× No keyword cloud information.
  15 in total

1.  Standards of medical care in diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

Review 2.  FIELDS of dreams, fields of tears: a perspective on the fibrate trials.

Authors:  A S Wierzbicki
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

3.  Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; Philip Barter; Rafael Carmena; Prakash Deedwania; Jean-Charles Fruchart; Steven Haffner; Judith Hsia; Andrei Breazna; John LaRosa; Scott Grundy; David Waters
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

4.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Authors:  Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

6.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

7.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

8.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; David Tanne; Valentina Boyko; Solomon Behar
Journal:  Arch Intern Med       Date:  2005-05-23

9.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

10.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.

Authors:  Frank B Hu; Meir J Stampfer; Steven M Haffner; Caren G Solomon; Walter C Willett; JoAnn E Manson
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.